ストックスクリーナーアプリを入手
0.3461
17.72%
0.0538
前日終値:
$0.2923
開ける：
$0.4201
24時間の取引高:
40.88M
Relative Volume:
48.20
時価総額：
$2.57M
収益：
-
当期純損益:
$-16.28M
株価収益率:
-0.0249
EPS:
-13.91
ネットキャッシュフロー:
$-13.75M
1週間 パフォーマンス:
-52.87%
1か月 パフォーマンス:
-52.10%
6か月 パフォーマンス:
-62.41%
1年 パフォーマンス:
-88.90%
1日の値動き範囲:
$0.32
$0.435
1週間の範囲:
$0.281
$0.7269
52週間の値動き範囲:
$0.281
$3.85
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
名前
Pasithea Therapeutics Corp
セクター
電話
(702) 514-4174
住所
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
KTTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.345 | 2.18M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.19 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.41 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.28 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
912.28 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.46 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pasithea Therapeutics Corp (KTTA) 最新ニュース
You might want to take a look at Pasithea Therapeutics Corp (KTTA) now - Setenews
Pasithea Therapeutics announces completion of cohort 7 in ongoing phase 1 trial of PAS-004 - MarketScreener
Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004 - TradingView
Pasithea reports positive safety data from PAS-004 cancer trial - Investing.com
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell? - Defense World
Pasithea Therapeutics says positive PAS-004 tablet pharmacokinetic data in ongoing Phase 1/1b trial in adult NF1 patients - MarketScreener
Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients - TradingView
Pasithea Therapeutics' PAS-004 Shows Favorable Pharmacokinetic Properties in Tablets in Phase 1 Trial - MarketScreener
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - Investing News Network
Pasithea reports positive PK data for PAS-004 tablet formulation By Investing.com - Investing.com India
Pasithea reports positive PK data for PAS-004 tablet formulation - Investing.com
Pasithea Therapeutics Announces Positive PAS-004 Tablet - GlobeNewswire
Pasithea Therapeutics Corp. (KTTA) -23.4% in Normal Trading: Despite Positive Phase 1 Data - Stocks Telegraph
Pasithea reports positive interim data for MEK inhibitor in cancer trial - Investing.com Canada
Real time scanner hits for Pasithea Therapeutics Corp. Equity Warrant explainedMarket Growth Summary & Technical Pattern Based Signals - newser.com
Pasithea Therapeutics announces positive phase 1 data including partial response - MarketScreener
Pasithea Therapeutics stock plunges after Phase 1 interim data release By Investing.com - Investing.com Nigeria
Pasithea Therapeutics stock plunges after Phase 1 interim data release - Investing.com
Pasithea reports positive interim data for MEK inhibitor in cancer trial By Investing.com - Investing.com South Africa
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Investing News Network
Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Its Stock Has Paid Off Big Time For Pasithea Therapeutics Corp - Setenews
Can Pasithea Therapeutics Corp. Equity Warrant stock resist sector downturns2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Why retail investors pile into Pasithea Therapeutics Corp. Equity Warrant stockGap Down & High Conviction Buy Zone Picks - newser.com
Is Pasithea Therapeutics Corp. Equity Warrant stock a buy for dividend growthEarnings Trend Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Pasithea Therapeutics Corp. stock is rated strong buy2025 Trade Ideas & Weekly Momentum Picks - newser.com
Does Pasithea Therapeutics Corp. Equity Warrant stock trade at a discount to peers2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Can Pasithea Therapeutics Corp. Equity Warrant stock beat market expectations this quarterFed Meeting & Low Drawdown Trading Strategies - newser.com
Is it too late to sell Pasithea Therapeutics Corp.July 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Pasithea Therapeutics Corp. (KTTA) AI-Powered Stock Analysis - Meyka
Is Pasithea Therapeutics Corp. Equity Warrant stock supported by strong cash flowsRisk Management & Daily Profit Focused Screening - newser.com
Combining price and volume data for Pasithea Therapeutics Corp.Market Risk Report & Daily Stock Momentum Reports - newser.com
Understanding Pasithea Therapeutics Corp. Equity Warrant’s price movementOil Prices & Weekly Watchlist for Consistent Profits - newser.com
Short interest data insights for Pasithea Therapeutics Corp.2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Is Pasithea Therapeutics Corp. stock cheap compared to fundamentalsIndex Update & Stock Portfolio Risk Management - newser.com
Multi factor analysis applied to Pasithea Therapeutics Corp.Trend Reversal & AI Enhanced Execution Alerts - newser.com
Pasithea Therapeutics Corp. stock chart pattern explained2025 Major Catalysts & Verified Momentum Stock Alerts - newser.com
Pasithea Therapeutics Corp. stock trend forecastQuarterly Profit Report & Daily Market Momentum Tracking - newser.com
How currency fluctuations impact Pasithea Therapeutics Corp. Equity Warrant stockJuly 2025 Breakouts & Reliable Trade Execution Plans - newser.com
[S-1] Pasithea Therapeutics Corp. Files IPO Registration Statement | KTTA SEC FilingForm S-1 - Stock Titan
Pasithea Therapeutics Corp (KTTA) 財務データ
収益
当期純利益
現金流量
EPS
Pasithea Therapeutics Corp (KTTA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
1.23%
5.82%
大文字化:
|
ボリューム (24 時間):